MedTrace Logo

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2026-03-12

No results posted yet for this study

Summary

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

Conditions

  • Episodic Migraine

Interventions

DRUG

Eptinezumab

Solution for infusion

DRUG

Placebo

Solution for infusion

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-08
Primary Completion
2027-07-06
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • Italy
  • Mexico
  • Poland
  • Portugal
  • Serbia
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05897320 on ClinicalTrials.gov